Prime Medicine (PRME) Non Operating Income (2021 - 2026)
Prime Medicine's (PRME) quarterly Non Operating Income came in at $1.5 million in Q1 2026, up 205.18% YoY from $502000.0 in Q1 2025, and down 39.42% on a QoQ basis from $2.5 million in Q4 2025.
Prime Medicine (PRME) Non Operating Income (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Non Operating Income data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Non Operating Income rose 205.18% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (up 88.38% YoY) and the FY2025 annual result came in at $7.2 million, up 9.46% from the prior year.
- Non Operating Income slipped to $1.5 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.4 million in Q3 2025 to a low of -$4.5 million in Q1 2022.
- A 5-year average of $910588.2 and a median of $1.5 million in 2026 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 525.35% in 2024, down 92.73% in 2024.
- Tracing PRME's Non Operating Income over 5 years: stood at -$783000.0 in 2022, then surged by 406.51% to $2.4 million in 2023, then declined by 18.92% to $1.9 million in 2024, then climbed by 29.96% to $2.5 million in 2025, then plunged by 39.42% to $1.5 million in 2026.
- The last three Non Operating Income figures came in at $1.5 million (Q1 2026), $2.5 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 1.53 Mn |
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 3.39 Mn |
| Jun 30, 2025 | 786,000.00 |
| Mar 31, 2025 | 502,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.71 Mn |
| Jun 30, 2024 | 211,000.00 |
| Mar 31, 2024 | 2.71 Mn |
| Dec 31, 2023 | 2.40 Mn |
| Sep 30, 2023 | 643,000.00 |
| Jun 30, 2023 | 2.90 Mn |
| Mar 31, 2023 | 434,000.00 |
| Dec 31, 2022 | -783,000.00 |
| Sep 30, 2022 | 2.52 Mn |
| Jun 30, 2022 | -3.49 Mn |
| Mar 31, 2022 | -4.47 Mn |
| Dec 31, 2021 | -1.45 Mn |
| Sep 30, 2021 | -8.36 Mn |